Point-of-Care Adipose-derived Cells for Hair Growth

Learn more about:
Related Clinical Trial
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss Anti-Androgen Treatment for COVID-19 A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss The Effect of Platelet Rich Plasma on Non-scarring Alopecia Optimizing Parameters for Long-pulsed Nd:YAG Laser for Reducing Hair Shaft Diameter HairDx Analytical Validation Study The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899) A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931) A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669) A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541) To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study To Evaluate the Pharmacokinetics and Safety of AD-208 The Utility of Platelet Rich Plasma in Hair Loss Computer-Assisted Versus Manual Hair Harvest Comparative Study Topical Bimatoprost Effect on Androgen Dependent Hair Follicles Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512) PAI-1 Expression in Non-scarring Hair Loss Split Wound Comparison of Trichophytic Closure Techniques for Donor Site in Hair Transplantation A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia Cold Plasma to Treat Hair Loss Adipose-derived SVF for Treatment of Alopecia Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss Photosensitization Study in Androgenetic Alopecia Point-of-Care Adipose-derived Cells for Hair Growth Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application Modulated Light Therapy in Participants With Pattern Hair Loss Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia N-Acetyl-Cysteine for Treatment of AGA in Men Clinical Trial in Females for Female Pattern Hair Loss Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5% Treatment of Androgenetic Alopecia in Males and Females Microarray Analysis of Scalp Biopsies After Minoxidil Treatment Efficacy of Platelet-Rich Plasma Therapy for Androgenetic Alopecia: A Systematic Review and Meta-analysis 24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Minoxidil Response Testing in Males With Androgenetic Alopecia Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution Treatment of Androgenetic Alopecia in Females, 9 Beam Treatment of Androgenetic Alopecia in Males With Theradome™ LH80 PRO Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing Treatment of Androgenetic Alopecia in Males Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Treatment of Androgenetic Alopecia in Females, 12 Beam Nanofat Grafting for Treatment of Androgenetic Alopecia Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Efficacy Study of a Cosmetic Lotion in the Treatment of Androgenetic Alopecia in Males and Females Treatment of Androgenic Alopecia in Males A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia Androgenetic Alopecia and the JAK-STAT Pathway Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia

Brief Title

Point-of-Care Adipose-derived Cells for Hair Growth

Official Title

Point-of-Care Adipose-derived Cells for Hair Growth

Brief Summary

      Androgenetic alopecia (AGA) is the most common form of hair loss and affects 50% and 23% of
      Caucasian men and women, respectively, over the age of 50. The percentage of men and women
      affected over the age of 70 increases to 80% and 60% of Caucasian men and women,
      respectively. Although alopecia is considered a minor dermatologic condition, it is seen as a
      serious condition with major life consequences by those with alopecia and has been associated
      with increased incidence of myocardial infarction, hypertension and hypercholesterolaemia.
      Androgenetic alopecia is associated with feelings of anxiety, depression and various
      personality disorders among men and women due to physical appearance. Depression, anxiety,
      aggressiveness, impaired quality of life and social inadequacy have been documented. The
      presence of alopecia in women is particularly stressful.

      ADSCs (Adipose Derived Stromal Cells), also called Stromal Vascular Fraction (SVF) cells,
      include regenerative cell populations derived from adipose tissue and thus are potentially
      important to multiple disease processes and therapeutic applications for the repair and
      regeneration of acute and chronically damaged tissues. It has been postulated that SVF cells
      may promote hair regeneration by increasing the hair-inducing ability of dermal papillae (DP)
      cells.

      The general objective of this study is to conduct a safety and feasibility study of a single
      injection of autologous adipose-derived SVF cells for the treatment of alopecia.
    

Detailed Description

      This is a prospective, non-randomized, non-blinded, interventional, consecutive series,
      single site study to determine initial safety and feasibility of a single injection of
      autologous adipose-derived SVF cells for the treatment of alopecia.

      Up to 8 subjects who have been diagnosed with androgenetic alopecia will be asked to
      participate. Before the procedure the density (number of hairs per square centimeter) and
      thickness (mm) of the hair will be measured and compared to the same measurements after the
      procedure. All adverse events will be recorded and evaluated for severity.

      Subjects will be asked to come into the office on the following days: pre-procedure visit, 24
      hours post procedure visit, 6 weeks post procedure visit, 3 months post procedure visit and 6
      months post procedure visit.
    


Study Type

Interventional


Primary Outcome

Incidence of treatment-emergent adverse events

Secondary Outcome

 Growth of new hair from baseline to 6 weeks, 3 months and 6 months

Condition

Androgenetic Alopecia

Intervention

Stromal Vascular Fraction Cells (SVF Cells) Injection

Study Arms / Comparison Groups

 Stromal Vascular Fraction Cells (SVF Cells)
Description:  The participants will undergo a standard tumescent liposuction to harvest adipose tissue. The adipose tissue will then be processed for obtain the Stromal Vascular Fraction Cells (SVF Cells) for a single injection for the treatment of androgenetic alopecia. Before the procedure, hair measurements will be performed in the 2cm x 2cm site for density (number of hairs per square centimeter) and thickness (mm) of the hair to compare to the measurements after the procedure at pre-procedure, 6 weeks, 3 months and 6 months.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Procedure

Estimated Enrollment

8

Start Date

October 2016

Completion Date

January 31, 2019

Primary Completion Date

January 31, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Subjects will be in good health (ASA Class I-II) with a BMI < 35.

          -  Must have at least a 2cm x 2cm spot on the scalp which shows evidence of alopecia
             without scarring or traumatic injury

          -  Able and willing to make the required study visits.

          -  Able and willing to give consent and follow study instructions.

          -  Must speak, read and understand English

        Exclusion Criteria:

          -  History of bleeding disorders, anticoagulation therapy that cannot be stopped 14 days
             prior to injection

          -  Allergic to lidocaine, epinephrine, Vancomycin, cephalexins, cephalosporins,
             penicillins, chlorhexidine gluconate, or tattoo ink

          -  Individuals with a propensity for keloids

          -  Individuals with diminished decision-making capacity will not be included in this
             research study.

          -  Current use of anti-inflammatory or anticoagulation medications that affect bleeding
             or are for bleeding disorders. These include: Plavix, Warfarin (Coumadin, Jantoven,
             Marfarin).

          -  Use of concomitant treatments to improve hair growth, including topical medications,
             oral medications, meso-therapy, non-ablative fractional laser treatment, low-level
             laser therapy, interfollicular PRP injection and hair transplantation within the
             preceding 6 months.

          -  Smoking and other tobacco use.

          -  Pregnancy or lactating period for females
      

Gender

All

Ages

18 Years - 60 Years

Accepts Healthy Volunteers

No

Contacts

Adam Katz, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT02729415

Organization ID

IRB201600420

Secondary IDs

ASVF-2016

Responsible Party

Sponsor

Study Sponsor

University of Florida


Study Sponsor

Adam Katz, MD, Principal Investigator, University of Florida


Verification Date

March 2019